BioSpace News Archive

SwiftScale Biologics announced it has successfully manufactured a COVID-19 neutralizing antibody candidate at clinical scale.

Menarini Silicon Biosystems, the pioneer of liquid biopsy and single cell technologies, announced that results from a new study presented at the virtual 2020 meeting of the American Society of Clinical Oncology suggest that circulating tumor cell counts may be useful in determining long-term prognosis and guiding treatment selection in patients with metastatic castrate sensitive prostate cancer.

Supporting the company’s global biomedical data and informatics platform and expansion in clinical diagnostics, pharmaceuticals, and medical centers

Veracyte, Inc. announced its submission of a De Novo classification request to the U.S. Food & Drug Administration for the nCounter® Dx LymphMark™ Assay, a novel, genomic lymphoma subtyping test.

The Ibn Sina Foundation announced it has launched rapid COVID-19 testing, together with CVS Health, at its Ibn Sina Wilcrest Community Clinic location.

Product manufactured by Hangzhou Biotest Biotech is confirmed by the National Cancer Institute to have specificity and sensitivity exceeding FDA requirements

Wayne County Community College District announced it has launched rapid COVID-19 testing, together with CVS Health, at its downtown campus site.

Enteris BioPharma, Inc. announced that John Vrettos, Ph.D., Senior Principal Scientist and Head of Formulation Development at Enteris, has been invited to participate in a webinar series hosted by BIODURO LLC highlighting advances in drug formulation and delivery.

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro will present at the Virtual Investor Fireside Chat Series on Wednesday, June 17, 2020 at 10:00 AM ET.

VerdePharmHealth today announced the signing of an exclusive national group purchasing agreement with Greene Street Pharmaceuticals that will utilize proprietary CBD-Cubed™ transdermal 24-hour delivery technology for multi-specialty patients.